S&P 500   4,569.68 (+0.32%)
DOW   35,453.78 (+0.10%)
QQQ   391.85 (+0.43%)
AAPL   190.86 (+0.24%)
MSFT   379.01 (-0.96%)
META   333.79 (-1.53%)
GOOGL   136.65 (-0.40%)
AMZN   146.95 (-0.05%)
TSLA   251.27 (+1.84%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.22 (-1.98%)
AMD   124.82 (+2.30%)
T   16.24 (+0.37%)
F   10.74 (+3.57%)
MU   77.78 (+2.18%)
CGC   0.55 (+1.50%)
GE   119.07 (+0.19%)
DIS   91.64 (-0.93%)
AMC   7.11 (+6.12%)
PFE   30.13 (+1.48%)
PYPL   59.01 (+0.92%)
XOM   103.46 (-0.42%)
S&P 500   4,569.68 (+0.32%)
DOW   35,453.78 (+0.10%)
QQQ   391.85 (+0.43%)
AAPL   190.86 (+0.24%)
MSFT   379.01 (-0.96%)
META   333.79 (-1.53%)
GOOGL   136.65 (-0.40%)
AMZN   146.95 (-0.05%)
TSLA   251.27 (+1.84%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.22 (-1.98%)
AMD   124.82 (+2.30%)
T   16.24 (+0.37%)
F   10.74 (+3.57%)
MU   77.78 (+2.18%)
CGC   0.55 (+1.50%)
GE   119.07 (+0.19%)
DIS   91.64 (-0.93%)
AMC   7.11 (+6.12%)
PFE   30.13 (+1.48%)
PYPL   59.01 (+0.92%)
XOM   103.46 (-0.42%)
S&P 500   4,569.68 (+0.32%)
DOW   35,453.78 (+0.10%)
QQQ   391.85 (+0.43%)
AAPL   190.86 (+0.24%)
MSFT   379.01 (-0.96%)
META   333.79 (-1.53%)
GOOGL   136.65 (-0.40%)
AMZN   146.95 (-0.05%)
TSLA   251.27 (+1.84%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.22 (-1.98%)
AMD   124.82 (+2.30%)
T   16.24 (+0.37%)
F   10.74 (+3.57%)
MU   77.78 (+2.18%)
CGC   0.55 (+1.50%)
GE   119.07 (+0.19%)
DIS   91.64 (-0.93%)
AMC   7.11 (+6.12%)
PFE   30.13 (+1.48%)
PYPL   59.01 (+0.92%)
XOM   103.46 (-0.42%)
S&P 500   4,569.68 (+0.32%)
DOW   35,453.78 (+0.10%)
QQQ   391.85 (+0.43%)
AAPL   190.86 (+0.24%)
MSFT   379.01 (-0.96%)
META   333.79 (-1.53%)
GOOGL   136.65 (-0.40%)
AMZN   146.95 (-0.05%)
TSLA   251.27 (+1.84%)
NVDA   482.61 (+0.92%)
NIO   7.32 (+1.53%)
BABA   75.22 (-1.98%)
AMD   124.82 (+2.30%)
T   16.24 (+0.37%)
F   10.74 (+3.57%)
MU   77.78 (+2.18%)
CGC   0.55 (+1.50%)
GE   119.07 (+0.19%)
DIS   91.64 (-0.93%)
AMC   7.11 (+6.12%)
PFE   30.13 (+1.48%)
PYPL   59.01 (+0.92%)
XOM   103.46 (-0.42%)

Altamira Therapeutics Stock Price, News & Analysis (NASDAQ:CYTO)

$0.21
-0.02 (-8.87%)
(As of 10:21 AM ET)
Compare
Today's Range
$0.20
▼
$0.21
50-Day Range
$0.10
▼
$0.37
52-Week Range
$0.09
▼
$6.16
Volume
811,108 shs
Average Volume
3.44 million shs
Market Capitalization
$1.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

CYTO stock logo

About Altamira Therapeutics Stock (NASDAQ:CYTO)

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.

CYTO Stock Price History

CYTO Stock News Headlines

November 20, 2023 | uk.finance.yahoo.com
Trending tickers: Microsoft | Bitcoin | Altamira | Ashtead
November 17, 2023 | msn.com
Altamira stock surges after deal to sell 51% stake in Medica
November 29, 2023 | Edge On The Street (Ad)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
November 17, 2023 | msn.com
Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today?
November 17, 2023 | marketwatch.com
Altamira Therapeutics Shares Surge on Sale of Bentrio Unit
November 17, 2023 | finance.yahoo.com
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
November 10, 2023 | finance.yahoo.com
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
November 3, 2023 | msn.com
Why Is Altamira Therapeutics (CYTO) Stock Up 28% Today?
November 29, 2023 | Edge On The Street (Ad)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
September 14, 2023 | marketwatch.com
Altamira Therapeutics Shares Rise on Positive Bentrio Trial Results
September 14, 2023 | finance.yahoo.com
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
September 13, 2023 | insidermonkey.com
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call Transcript
September 12, 2023 | finanznachrichten.de
Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 12, 2023 | finance.yahoo.com
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 8, 2023 | markets.businessinsider.com
Altamira Therapeutics Ltd Registered Shs hosts conference call for investors
September 6, 2023 | finance.yahoo.com
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
August 23, 2023 | uk.finance.yahoo.com
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
August 23, 2023 | finance.yahoo.com
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
July 20, 2023 | finance.yahoo.com
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
July 17, 2023 | finance.yahoo.com
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
July 6, 2023 | msn.com
Why Altamira Therapeutics (CYTO) Stock Is Getting Hammered
July 6, 2023 | finance.yahoo.com
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
July 5, 2023 | finance.yahoo.com
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
June 15, 2023 | finance.yahoo.com
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
May 31, 2023 | finance.yahoo.com
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets
May 24, 2023 | finance.yahoo.com
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
May 18, 2023 | benzinga.com
Altamira Therapeutics Stock (NASDAQ:CYTO), Analyst Ratings, Price Targets, Predictions
See More Headlines
Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
11/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTO
CUSIP
N/A
CIK
1601936
Web
www.aurismedical.com
Phone
(441) 295-5950
Fax
41-61-201-1351
Employees
16
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.32
Quick Ratio
0.27

Sales & Book Value

Annual Sales
$320,000.00
Price / Sales
5.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($7.38) per share
Price / Book
-0.03

Miscellaneous

Outstanding Shares
6,990,000
Free Float
6,078,000
Market Cap
$1.61 million
Optionable
Not Optionable
Beta
1.66
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Thomas Meyer Ph.D. (Age 55)
    Founder, Chairman, CEO & MD
    Comp: $566.88k
  • Mr. Marcel Gremaud CPA (Age 65)
    Chief Financial Officer
  • Dr. Covadonga Paneda (Age 49)
    Chief Operating Officer
  • Dr. Samuel A. Wickline M.D. (Age 70)
    Chief Scientific Adviser

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions














CYTO Stock Analysis - Frequently Asked Questions

How have CYTO shares performed in 2023?

Altamira Therapeutics' stock was trading at $4.85 at the beginning of the year. Since then, CYTO shares have decreased by 95.7% and is now trading at $0.2097.
View the best growth stocks for 2023 here.

Are investors shorting Altamira Therapeutics?

Altamira Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 514,300 shares, an increase of 181.5% from the October 31st total of 182,700 shares. Based on an average daily volume of 8,950,000 shares, the days-to-cover ratio is currently 0.1 days.
View Altamira Therapeutics' Short Interest.

When did Altamira Therapeutics' stock split?

Altamira Therapeutics's stock reverse split on Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Altamira Therapeutics' major shareholders?

Altamira Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (11.86%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Altamira Therapeutics?

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTO) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -